SOURCE-LINKED STUDY SUMMARY
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.
Abstract summarizedQuality not appraised
- What was studied
- A prespecified SELECT analysis examined long-term weight, body measurements, safety and tolerability with semaglutide versus placebo.
- Who / model studied
- SELECT enrolled adults with preexisting cardiovascular disease and overweight or obesity, without diabetes.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Semaglutide produced greater weight and waist reductions than placebo, with weight loss sustained over four years.
- Limitations & context
- Trial-product discontinuation was increased with semaglutide and rose as BMI class decreased.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1038/s41591-024-02996-7